NCT02596503 2022-02-15
A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors
University of Colorado, Denver
Phase 1 Completed
University of Colorado, Denver
Eisai Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eisai Inc.